ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Renal Transplant Induction Therapy Safety Outcomes Comparison

R. M. Hofmann1, J. Combs2, K. J. Schmidt3, T. Dyckman4

1Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, 2Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, 3Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, 4Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI

Meeting: 2020 American Transplant Congress

Abstract number: C-001

Keywords: Antilymphocyte antibodies, Induction therapy, Monoclonal antibodies, Neutropenia

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session C: Kidney Immunosuppression: Induction Therapy

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients
  • Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.

*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents but less is known regarding differences in safety. Specifically, prolonged leukopenia may prompt dose reductions in maintenance medications, potentially increasing risk for infection and rejection. We sought to characterize the safety of alemtuzumab compared to r-ATG when used for induction therapy following kidney transplant.

*Methods: Kidney transplant patients 18 years of age or older that received alemtuzumab or r-ATG from January 1, 2009 through December 31, 2014 were retrospectively evaluated. Patients with a prior kidney transplant receiving a pre-emptive transplant or those that received desensitization with rituximab or intravenous immunoglobulin prior to transplant were excluded. The primary outcome was incidence of leukopenia within 12 months of transplant. Secondary outcomes included incidence of maintenance medication adjustments, infection and biopsy proven acute rejection (BPAR).

*Results: In total, 340 patients (218 receieved alemtuzumab, 122 received r-ATG) were analyzed. Incidence of leukopenia within 12 months of transplant was similar between groups (56.9% alemtuzumab vs 59.0% r-ATG, p=0.789). The incidence of mycophenolic acid derivative dose decreases within the first 3 months of transplant was higher in the alemtuzumab group (70.2% vs 56.6%, p=0.016). Anti-infective prophylaxis dose adjustments, were similar between groups. The incidence of infections requiring hospitalization within 1 year of transplant was also similar between groups (21.6% alemtuzumab vs 29.5% r-ATG, p=0.121). BPAR within 1 year of transplant was higher in the r-ATG group (5.0% vs 11.5%, p=0.047) but the overall rate at 3 years post-transplant was similar. Accounting for other known risk factors, r-ATG was found to be a significant predictor for BPAR at 1 year post-transplant along with cytomegalovirus infection within 1 year of transplant.

*Conclusions: We failed to demonstrate a significant difference in prolonged leukopenia rates between kidney transplant patients that received alemtuzumab versus r-ATG. With similar safety profiles, and potentially lower efficacy with r-ATG, alemtuzumab may be the preferred induction immunosuppressant following kidney transplantation; however, patients receiving thymoglobulin tend to be higher immunologic risk which may affect the rate of BPAR post-transplant. Patients in our study were not stratified according to immunologic risk.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hofmann RM, Combs J, Schmidt KJ, Dyckman T. Renal Transplant Induction Therapy Safety Outcomes Comparison [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-transplant-induction-therapy-safety-outcomes-comparison/. Accessed January 23, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
    • Penis Transplantation: First U.S. Experience.
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Home
    • Search
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.